Lung, Tom; Clarke, Philip; Hayes, Alison; Stevens, Richard - In: PharmacoEconomics 31 (2013) 6, pp. 509-518
The model incorporates diabetic complications risk data from a type 1 diabetes population and synthesizes other type 1—specific data to estimate long-term outcomes of CVD, end-stage renal disease, LEA and risk of blindness, along with life expectancy and QALYs. External validation was carried...